| Literature DB >> 31332488 |
Runjie Song1, Qing Zhai2, Lu Sun1, Enxia Huang1, Yu Zhang1, Yanli Zhu1, Qingyun Guo3, Yanan Tian4, Baoyu Zhao1, Hao Lu5.
Abstract
Filamentous fungi play an important role in human health and industrial/agricultural production. With the increasing number of full genomes available for fungal species, the study of filamentous fungi has brought about a wider range of genetic manipulation opportunities. However, the utilization of traditional methods to study fungi is time consuming and laborious. Recent rapid progress and wide application of a versatile genome editing technology, i.e., the CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR-related nuclease 9) system, has revolutionized biological research and has many innovative applications in a wide range of fields showing great promise in research and application of filamentous fungi. In this review, we introduce the CRISPR/Cas9 genome editing technology focusing on its application in research of filamentous fungi and we discuss the general considerations of genome editing using CRISPR/Cas9 system illustrating vector construction, multiple editing strategies, technical consideration of different sizes of homology arms on genome editing efficiency, off-target effects, and different transformation methodologies. In addition, we discuss the challenges encountered using CRISPR/Cas9 technology and give the perspectives of future applications of CRISPR/Cas9 technology for basic research and practical application of filamentous fungi.Entities:
Keywords: CRISPR/Cas9; Filamentous fungi; Genome editing; Off-target
Year: 2019 PMID: 31332488 PMCID: PMC6690858 DOI: 10.1007/s00253-019-10007-w
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Fig. 1Schematic illustration of Cas9/gRNA genome editing. a sgRNA-mediated Cas9 protein can bind to target sequences of site and cut DNA double strands. b When the DNA double-strand breaks occur, the cell initiates the self-repair mechanism. The NHEJ-dominated repair pathway will cause the random loss, insertion, and replacement of bases at the breakage point, resulting in gene mutation. The HR pathway will accurately edit the target gene guided by the donor DNA fragment. c Single-promoter-driven gRNA expression cassette. d multiple gRNA expression cassettes can be constructed by concatenating 2 or more of gRNA linked together by linkers, which can then be enzymatically processed into multiple single gRNAs thus targeting multiple sites
Fig. 2The history of the development and application of CRISPR/Cas9 technology in filamentous fungi; different colors represent different promoter-driven gRNA expression cassettes
The application of the CRISPR/Cas9 system in filamentous fungi
| Species | Cas9 expression (selection marker, promoter) | Delivery method | Editing method | Application and efficiency | Reference |
|---|---|---|---|---|---|
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single/multiple-gene disruption ⩾ 93%/4.2–45% | Liu et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single-gene disruption, 36.1–80.5% | Arazoe et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Nodvig et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single-gene disruption | Matsu-Ura et al. |
|
| Human codon-optimized Cas9, | PMT | NHEJ | Single-gene disruption, 25%-53% | Fuller et al. |
|
| Human-optimized codons Cas9, | PMT | NHEJ/HDR | Single-gene disruption | Fang and Tyler |
|
| Codon-optimized Cas9, | PMT | NHEJ | Single/double-gene disruption, 50%-90% | Schuster et al. |
|
| Human codon-optimized Cas9, | PMT | HDR | Single/double-gene disruption, 95%-100% | Zhang et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ | Single-gene disruption, 10–20% | Katayama et al. |
|
| Human codon-optimized Cas9, | PMT | NHEJ/HDR | Single-gene disruption, 100% | Pohl et al. |
|
| Codon-optimized Cas9, | Lithium acetate | NHEJ/HDR | Single-gene disruption | Min et al. |
|
| pFC332, | PMT | NHEJ/HDR | Weber et al. | |
|
| pFC332, | PMT | NHEJ/HDR | Single-gene disruption, 37.5–100% | Kuivanen et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ | Multiple-gene disruption, 50–90% | Schuster et al. |
| Codon-optimized Cas9, | PMT/AMT | NHEJ/HDR | Single/multiple-gene disruption, 15–95% | Liu et al. |
|
| pFC330, | PMT | NHEI | Single-gene disruption | Nielsen et al. |
|
| pFC332, | AMT | NHEJ/HDR | Single-gene disruption, 27% | Weyda et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Kuivanen et al. |
|
| Codon-optimized Cas9, | PMT | NHEI | Single-gene disruption, | Qin et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single/multiple-gene disruption, 5–50% | Chen et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Wenderoth et al. |
|
| Codon-optimizedCas9, | PMT | NHEJ | Single-gene disruption | Deng et al. |
|
| Codon-optimizedCas9, | PMT | NHEJ/HDR | Single-gene disruption, 32% | Deng et al. |
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single-gene disruption | Zheng et al. | |
|
| SpCas9, | PMT | NHEJ/HDR | Single/double-gene disruption, 100% | Nagy et al. |
|
| Codon-optimized Cas9, fludioxonil, | PMT | NHEJ/HDR | Single-gene disruption, 1–10% | Gardiner and Kazan |
|
| Human codon-optimized Cas9, | AMT | NHEJ | Single-gene disruption | Idnurm et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Kuivanen and Richard |
|
| SpCas9, | Electroporation | NHEJ | Double-gene disruption, 53–98% | Shapiro et al. |
|
| pFC332, argB/pyrG, tef1 | AMT | HDR | Multiple-gene disruption, 15–90% | Nodvig et al. |
|
| pFC332, | AMT | NHEJ | Single/double-gene disruption, 22–73% | Kujoth et al. |
|
| Codon-optimized Cas9, | PMT | NHEL/HDR | Single-gene disruption, 33.3–100% | Zheng et al. |
|
| Codon-optimized Cas9, | Electroporation | HDR | Single/double-gene disruption, 25–100% | Vyas et al. |
|
| Human-optimized codons Cas9, | PMT | NHEJ | Double-gene disruption | Miao et al. |
|
| pFC332, | PMT | NHEJ/HDR | Single-gene disruption, 20–53.8% | Wang et al. |
|
| Codon-optimized Cas9, | AMT PMT | NHEJ | Multiple-gene disruption, 60%-90% | Liang et al. |
|
| Codon-optimized Cas9, | AMT/PMT | NHEJ/HDR | Single-gene disruption, 87.2–84.3% | Chen et al. |
|
| Codon-optimized Cas9, | Electroporation | HDR | Single-gene disruption, 96.5–100% | Wang |
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single-gene disruption, 38–100% | Li et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Matsuda et al. |
|
| pFC332, argB/pyrG, | PMT | HDR | Single-gene disruption, 100% | Leynaud-Kieffer et al. |
|
| Codon-optimized Cas9, | PMT | HDR | Single/double-gene disruption, 50–100% | Katayama et al. |
|
| pFC332, | PMT | NHEJ | Single-gene disruption | Igbalajobi et al. |
|
| Codon-optimized Cas9, | PMT | NHEJ/HDR | Single/multiple-gene disruption 100% | Kuivanen et al. |
|
| SpCas9, | PMT | HDR | Multiple-gene disruption 100% | Nagy et al. |
|
| Human codon-optimized Cas9, | AMT | NHEJ | Double-gene disruption | Darma et al. |
|
| Human-optimized codons Cas9, | Electroporation | NHEJ | Single-gene disruption, 44–85% | Jiménez et al. |
|
| pFC332, | PMT | HDR | Single-gene disruption | Loubna et al. |